Chronic Kidney Disease
Part of NephTimes
A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia. Eli Lilly ended a phase II trial of volenrelaxin in chronic kidney disease "due to a lack of foreseeable clinical benefit." Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is unclear. Using NURTuRE-CKD data, researchers studied kidney outcomes and heterogeneity of risk by primary renal diagnosis. Monlunabant failed in a study of its use in DKD, but Novo Nordisk had positive news about other kidney treatments in 2024. Can SZC help with RAASi maximization without resultant hyperkalemia in patients with HFrEF and CKD? A study assessed the kidney benefits of metabolic surgery compared to GLP-1RA treatment in patients with obesity and CKD. Does the prevalence of cardiovascular-kidney-metabolic syndrome stages vary by social determinants of health? The FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes. A study examined the clinical relevance of urinary mRNA levels in patients with IgA nephropathy (IgAN). A study examined the efficacy and safety of conversion from treatment with the long-acting ESA MPG-EPO to vadadustat. Researchers examined ULT and the risk of CKD progression among patients with impaired kidney function and gout. What is the association of gout with CV disease and mortality risk in patients with type 2 diabetes and can CKD modify it? A secondary analysis of DCP trial data sought to understand the effects of thiazide diuretics on kidney outcomes. Researchers studied the association between chronic kidney disease and postoperative complications. Researchers studied the association of obesity severity and duration with chronic kidney disease incidence. The FDA rejected Zynquista as an add-on to insulin therapy for adults with type 1 diabetes and CKD. A global review noted changes in kidney care delivery but revealed gaps in access to kidney replacement therapies. A study examined the association of APOL1 risk variants and genotypes with chronic kidney disease among West Africans. The European label for Ozempic will be updated to include risk reduction for events related to kidney disease.